Which is better, cabozantinib or anlotinib?

Cabozantinib (Cabozantinib) and Anlotinib are two targeted drugs used to treat tumors. They have similar mechanisms of action and indications to a certain extent. Both drugs have shown certain efficacy in clinical application, but which one is better depends on the individual situation and the patient's specific disease type, so it is impossible to simply judge which one is better.

Cabozantinib is mainly used to treat advanced renal cell carcinoma, advanced hepatocellular carcinoma and medullary thyroid cancer. It is an oral drug that inhibits multiple signaling pathways required for tumor growth and metastasis, including angiogenesis and bone resorption, and has the ability to inhibit tumor cell invasion and migration. Common adverse reactions include hypertension, diarrhea, fatigue, etc. Anlotinib is a targeted therapy drug for non-small cell lung cancer, mainly targeting patients with positive ALK or ROS1 gene rearrangements. Anlotinib can inhibit the expression of these genes, thereby inhibiting the growth and spread of tumor cells. Adverse reactions include high blood pressure, fatigue, loss of appetite, etc.

The original drug Cabozantinib is not marketed in the country and therefore cannot be included in medical insurance. The original cabozantinib drug marketed overseas includes Japanese, European and Turkish versions. The price of tablets may be more than 30,000 yuan, and the price of capsule preparations may be more than 40,000 yuan (prices may fluctuate due to exchange rates). There are also generic drugs produced in other countries overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. For example, the price of pharmaceuticals produced by Bangladeshi pharmaceutical factories may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), which is relatively cheap.